Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 23;39(4):767–785. doi: 10.1038/s41388-019-1023-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — T210 of PLK1 is highly phosphorylated, but S137 is not in TGF-β-induced epithelial mesenchymal transition (EMT). a Heat maps were generated from TCGA lung adenocarcinoma patients’ dataset. Heat map showed the expression profile of genes, including PLK1, epithelial markers (Epi), mesenchymal markers (Mes), and proliferation markers (Pro) in paired normal and tumor tissues with stage 1 (right) or stages 2–4 (left). *4625 has missense mutation (S335C). b Cumulative overall survival of all NSCLC patients (left) and TMN stage N2 patients (right) according to PLK1 expression. Kaplan–Meier plot of overall survival rates for NSCLC patients was generated by splitting patients by their PLK1 expression levels (defined using median values), and the data were analyzed based on the log-rank test (left, n = 1926, HR = 1.66, log rank p = 3.3e-15; right, n = 111, HR = 1.48, log rank p = 0.05). c Expression and phosphorylation of PLK1 was measured using PLK1 and p-PLK1 (T210) antibodies in normal MRC5 lung cells, primary NSCLC A549, and metastatic NSCLC NCI-H460, NCI-H1299, and NCI-H358 cells. d A heat map analysis was performed for PLK1, epithelial marker CDH1 or OCLN, and several mesenchymal markers, including CDH2, using a published transcriptome of TGF-β-treated NSCLC (GSE 114761). e–g MRC5, A549, NCI-H460, and NCI-H1299 cells were treated with 2.5 ng/ml of TGF-β for 48 h. e qRT-PCR was performed for PLK1, CDH1, CDH2, and VIM expression using TGF-β-treated MRC5, A549, NCI-H460, and NCI-H1299 cells. *p < 0.05; **p < 0.01; ***p < 0.001. (n = 3). Data presented as mean ± SD. f Immunoblot analyses were performed for PLK1, p-T210-PLK1, p-S137-PLK1, N-cadherin, E-cadherin, vimentin, snail, slug, and β-actin using specific antibodies with lysates from MRC5, A549, NCI-H460, and NCI-H1299 cells treated with TGF-β. g The band intensity values of p-T210-PLK1, p-S137-PLK1, and PLK1 were quantified using LI-COR Odyssey software (Li-COR Biosciences). The band intensity values of p-T210-PLK1 and p-S137-PLK1 were normalized to those of PLK1 and plotted